Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz


1. Momelotinib Dihydrochloride Monohydrate
2. Ldx8893l5d
3. Cyt-387 Dihydrochloride Monohydrate
4. Cyt-11387 Dihydrochloride Monohydrate
5. Momelotinib Hydrochloride Hydrate (jan)
6. Momelotinib Hydrochloride Hydrate [jan]
7. Benzamide, N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)-, Hydrochloride, Hydrate (1:2:1)
8. Benzamide, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-, Hydrochloride, Hydrate (1:2:1)
9. N-(cyanomethyl)-4-(2-(4-(morpholin-4-yl)anilino)pyrimidin-4-yl)benzamide Dihydrochloride Monohydrate
10. N-(cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide Dihydrochloride Monohydrate
11. Unii-ldx8893l5d
12. Ojjaara
13. 1841094-17-4
14. Ojjaara (tn)
15. Omjjara (tn)
16. Schembl17333087
17. D10889
| Molecular Weight | 505.4 g/mol |
|---|---|
| Molecular Formula | C23H26Cl2N6O3 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 6 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 104 |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 615 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 4 |
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
43
PharmaCompass offers a list of Momelotinib Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Momelotinib Hydrochloride manufacturer or Momelotinib Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Momelotinib Hydrochloride manufacturer or Momelotinib Hydrochloride supplier.
A Momelotinib Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Momelotinib Hydrochloride, including repackagers and relabelers. The FDA regulates Momelotinib Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Momelotinib Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Momelotinib Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Momelotinib Hydrochloride supplier is an individual or a company that provides Momelotinib Hydrochloride active pharmaceutical ingredient (API) or Momelotinib Hydrochloride finished formulations upon request. The Momelotinib Hydrochloride suppliers may include Momelotinib Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Momelotinib Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Momelotinib Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Momelotinib Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Momelotinib Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Momelotinib Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Momelotinib Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Momelotinib Hydrochloride suppliers with NDC on PharmaCompass.
Momelotinib Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Momelotinib Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Momelotinib Hydrochloride GMP manufacturer or Momelotinib Hydrochloride GMP API supplier for your needs.
A Momelotinib Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Momelotinib Hydrochloride's compliance with Momelotinib Hydrochloride specifications and serves as a tool for batch-level quality control.
Momelotinib Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Momelotinib Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Momelotinib Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Momelotinib Hydrochloride EP), Momelotinib Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Momelotinib Hydrochloride USP).